Thalidomide dose proportionality assessment following single doses to healthy subjects

• Published in: Journal of clinical pharmacology Vol. 41; no. 6; p. 662
• Main Authors: Teo, S K, Scheffler, M R, Kook, K A, Tracewell, W G, Colburn, W A, Stirling, D I, Thomas, S D
• Format: Journal Article
• Language: English
• Published: England 01.06.2001
• Subjects: Adult; Area Under Curve; Body Weight; Female; Humans; Leprostatic Agents - administration & dosage; Leprostatic Agents - adverse effects; Leprostatic Agents - blood; Leprostatic Agents - pharmacokinetics; Male; Middle Aged; Thalidomide - administration & dosage; Thalidomide - adverse effects; Thalidomide - blood; Thalidomide - pharmacokinetics

Thalidomide is approved in the United States for treating erythema nodosum leprosum, a complication of leprosy. The present study determined the single-dose oral pharmacokinetics and dose proportionality from 50 to 400 mg of Celgene's commercial Thalomid thalidomide formulation in an open-label...